Professor Denise Kelly joined Seventure Partners, a European Leader in Venture Capital, in 2015 as an Investment Advisor to the Life Sciences Team and is focused specifically, on Human Microbiome investment opportunities across Europe and the USA.
Prior to joining Seventure, Denise was Head of her Research team at the World-renowned Rowett Institute, University of Aberdeen, where she acquired over 20 years experience in gut microbiology and immunology. She was the (former) Founder Director, CEO and CSO of GT Biologics Ltd, one of the first translational spinouts, developing Innovative Microbiome-based Therapies. She is the main inventor on numerous EU and USA patent applications and during her career has collaborated with pharmaceutical and healthcare companies on several translational projects.
Denise holds a BSc and PhD from Queen’s University, Belfast and an Emeritus Professorship from the University of Aberdeen.